Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
17/10/2025 12:41
Oct 17 (Reuters) - Rani Therapeutics RANI.O said on Friday it has agreed a deal to license an oral drug to Japan's Chugai Pharmaceutical 4519.T, with an option to extend it to up to five drugs, potentially bringing the total deal value to $1.09 billion. (Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)